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The phosphatidylinositol 3-kinases (PI3Ks) are members of a family of intracellular lipid
kinases that phosphorylate the 3′-hydroxyl group of phosphatidylinositol and phosphoinosi-
tides. PI3K regulate signaling pathways for neoplasia, including cell proliferation, adhesion,
survival, and motility. Different classes of PI3K have distinct roles in cellular signal trans-
duction. PI3K pathway is activated by several different mechanisms in cancers, including,
somatic mutation and gene ampliﬁcation. In this review, we examine the literature address-
ing PI3K mutation status and gene ampliﬁcation, with an emphasis on non-small cell lung
cancer.
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PI3K CLASSIFICATION
The phosphatidylinositol 3-kinases (PI3Ks) are members of a
family of intracellular lipid kinases that phosphorylate the 3′-
hydroxyl group of phosphatidylinositol and phosphoinositides.
This reaction leads to the activation of many intracellular sig-
naling pathways that regulate functions such as cell proliferation,
adhesion, survival, and motility (Figure 1).
Phosphatidylinositol 3-kinases are grouped into three classes
(I, II, III) according to their substrate preference and sequence
homology. Different classes of PI3K have distinct roles in cellu-
lar signal transduction, as do the different isoforms that can exist
within each class (Engelman et al., 2006).
In mammals, numerous genes encode different isoforms of
PI3Ks (Fruman et al., 1998).
CLASS IA PI3K
This is the most clearly implicated class in human cancers (Yuan
and Cantley, 2008). Class IA PI3K is a heterodimer that consists of
a p85 regulatory subunit and a p110 catalytic subunit. Three genes,
PIK3R1, PIK3R2, and PIK3R3 encode the p85α, p85β, and p55γ
isoforms of the p85 regulatory subunit, respectively. The PIK3R1
gene also gives rise to two shorter isoforms, p55α and p50α. The
Class IA p85 regulatory isoforms have a common core structure
consisting of a p110-binding domain [also called the inter-Src-
homology 2 (inter-SH2) domain] ﬂanked by two SH2 domains
(Huang et al., 2007). The p85 regulatory subunit is crucial inmedi-
ating the activation of class IA PI3K by receptor tyrosine kinases
(RTKs).
Three genes – PIK3CA, PIK3CB, and PIK3CD – encode the
highly homologous p110 catalytic subunit isoforms p110α, p110β,
and p110δ, respectively (Cantley, 2002). The p110α subunit of
PI3Kα has ﬁve domains: an N-terminal domain called adaptor
binding domain (ABD), that binds to p85α, a Ras-binding domain
(RBD), a domain called C2 that has been proposed to bind to cel-
lular membranes, a helical domain, and a kinase catalytic domain
(Vanhaesebroeck andWaterﬁeld, 1999;Cantley, 2002;Huang et al.,
2007).
In mammals, class I PI3Ks are involved in cellular grow-
ing, proliferation, motility, cell survival, and intracellular trafﬁc.
Class I PI3K also regulates glucose homeostasis: insulin receptor
substrate.
CLASS IB PI3K
Class IB PI3K is a heterodimer consisting of a p101 regulatory sub-
unit and a p110γ catalytic subunit. In 2005 two other regulatory
subunits, p84 and p87 PIKAP (phosphoinositide 3-kinase gamma
adapter protein of 87 kDa) were described.
CLASS II PI3K
Class II PI3K consists of only a p110-like catalytic subunit. The
three isoforms of class II-PIK3C2α, PIK3C2β, and PIK3C2γ are
encoded by distinct genes. Relatively little is known about the
function of class II.
CLASS III PI3K
Class III PI3Ks consist of a single member, Vps34 (vacuolar sort-
ing protein 34) which has been implicated in phagocytosis in the
system immune and in trafﬁc proteins and vesicles.
PI3K SIGNALING CASCADE
All major elements of the PI3K pathway have been found mutated
or ampliﬁed in a broad range of cancers. The axis of PI3K sig-
naling in cancer begins with engagement of growth factors by
receptor tyrosine kinases (RTKs). These RTKs are often mutated,
ampliﬁed, or overexpressed, causing aberrant PI3K activation. For
example, PI3K is activated by epithelial growth factor receptor
(EGFR) in lung cancers harboring somatic activating mutations
in EGFR (Skolnik et al., 1991; Engelman and Settleman, 2008). In
this cancer,EGFRdirectly binds and activates PI3K. The regulatory
subunit, p85, directly binds to phosphotyrosine residues on RTKs
and/or adaptors (Carpenter et al., 1993). This binding relieves the
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FIGURE 1 |The phosphatidylinositol 3-kinase (PI3K) signaling cascade.
Class Type Vertebrates
Class IA Catalytic PIK3CA (p110α)
PIK3CB (p110β)
PIK3CD (p110δ)
Regulatory PIK3R1 (p85α/55α/p50α)
PIK3R2 (p85β)
PIK3R3 (p55γ)
Class IB Catalytic PIK3CG (p110γ)
Regulatory PIK3R5 (p101)
p84
PIK3R6 (p87PIKAP)
Class II Catalytic PIK3C2α
PIK3C2β
PIK3C2γ
Class III Catalytic VP534
Regulatory PIK3R4 (p150)
intermolecular inhibition of the p110 catalytic subunit by p85 and
localizes PI3K to the plasma membrane where its substrate, phos-
phatidylinositol 4,5-bisphosphate (PIP2), resides (Zhao and Vogt,
2008). PI3K can also be stimulated by activated Ras,which directly
binds p110 (Shaw and Cantley, 2006). Additionally, the p110β cat-
alytic subunit can be activated by G-protein coupled receptors
(Katso et al., 2001).
Phosphatidylinositol 3-kinases is then recruited to plasma
membrane-anchored receptors and is activated and phosphory-
lates PIP2 on the 3′OH position to produce phosphatidylinositol
3,4,5-trisphosphate (PIP3). The tumor suppressor phosphatase
and tensinhomologdeletedon chromosome10 (PTEN)negatively
regulates PI3K; dephosphorylates PIP3 to PIP2, thereby termi-
nating PI3K-dependent signaling (Courtney et al., 2010). PIP3
propagates intracellular signaling by directly binding pleckstrin
homology (PH) domains of various signaling proteins (Cant-
ley, 2002). Phosphatidylinositol-3,4,5-trisphosphate (PIP3) prop-
agates intracellular signaling as a second messenger activating
many downstreammolecules. The protein serine/threonine kinase
AKT (also known as PKB) is a principal target of PIP3 (Franke
et al., 1997). Binding of PIP3 to AKT leads to the membrane
recruitment of AKTand subsequent phosphorylationby themam-
malian target of rapamycin (mTOR)-rictor kinase complex and
by 3-phosphoinositide-dependent kinase (PDK1; Sarbassou et al.,
2005). The full activation of AKT phosphorylates many target
proteins, such as forkhead (FOXO) family of transcription factors.
AKT promotes cell survival by inhibiting pro-apoptotic Bcl2
family members BAD and BAX (Cantley, 2002). AKT also can
phosphorylate MDM2 leading to p53 degradation (Vivanco and
Sawyers, 2002). AKT phosphorylates and inactivates the FOXO
family of transcription factors. FOXO proteins promote the
expression of pro-apoptotic genes, such asBim and Fas and p27Kip
and retinoblastoma-like2 (RBL2) to inhibit cell-cycle entry and cell
survival.
AKT mediates cell metabolism by activating glycogen synthase
through the inhibition of glycogen synthase kinase 3 (GSK3).
AKT regulate protein synthesis by phosphorylating the tuberous
sclerosis complex 2 (TSC2) protein tuberin, and therefore inhibits
the GTPase-activating protein (GAP) activity of the TSC1–TSC2
complex toward Rheb. This allows GTP-bound Rheb to accumu-
late and activate the mTOR-raptor kinase complex, which in turn
mediates phosphorylation of 4E-BP1 and p70, ultimately leading
to increased protein synthesis (Richardson et al., 2004).
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IMPLICATIONS FOR DIABETES
The p85 regulatory subunit is required for the stabilization of
p110 and for the activation of PI3K by the insulin receptor. A
partial reduction in p85 levels leads to improved PI3K signaling
and increased insulin sensitivity in vivo. PI3K signaling mediates
different cellular responses depending on the tissue context, and
defective PI3K signaling in many tissues contributes collectively
to the complex metabolic defects associated with type-2 diabetes
(Hansen et al., 1997; Barroso et al., 2003). Elevated levels of p85
have been observed in women with pregnancy-induced insulin
resistance (Kirwan et al., 2004). Similarly, elevated levels of p85,
but not p110, were observed in muscles of type-2 diabetic indi-
viduals, indicating that increased levels of p85 might contribute to
muscle insulin resistance in diabetes.
FREQUENCY OF MUTATIONS AND AMPLIFICATIONS IN THE
PI3K PATHWAY IN NSCLC
Receptor tyrosine kinases upstream of PI3K, the p110α catalytic
subunit of PI3K, the downstream kinase, AKT, and the negative
regulator, PTEN, are all frequently altered in cancer. The PIK3CA
gene that encodes p110α is also ampliﬁed at high frequencies in
squamous cell lung carcinoma (Engelman et al., 2006). PIK3CA
and PIK3R1 are somatically mutated in cancers, and these muta-
tions promote activation of the PI3K pathway (Ikenoue et al.,
2005).
Huang et al. (2007) reported a 3.0-Å resolution structure of a
complex between p110α and a polypeptide containing the p110α-
binding domains of p85α, a protein required for its enzymatic
activity (Vanhaesebroeck and Waterﬁeld, 1999). The structure
showed that many of the mutations occurred at residues lying
at the interfaces between p110α and p85α or between the kinase
domain of p110α and other domains within the catalytic subunit.
The twomost common geneticmutations that directly activate the
PI3K signaling pathway are somatic activatingmutations of p110α
(PIK3CA) and loss of the tumor suppressor PTEN.
Additionally, ampliﬁcation of PIK3CA and AKT are occasion-
ally observed in epithelial cancers (Engelman et al., 2006). In
non-small cell lung cancer (NSCLC), mutations in PIK3CA and
PTEN are uncommon, although there are reports demonstrating
evidence for loss of PTENprotein expression andPIK3CA ampliﬁ-
cation (Massion et al., 2002;Marsit et al., 2005). Somaticmutations
in PIK3CA have been identiﬁed in a variety of human tumors,
including NSCLC. Most of these mutations in p110α cluster to
two hot spot regions in exons 9 and 20 (>75%). Exon 20 encodes
the catalytic domain of p110α (H1047R); exon 9 encodes the heli-
cal domain of p110α (E545K; Samuels and Velculescu, 2004). A
smaller cluster of mutations is also found in the N-terminal p85
interacting domain. While activating mutations in PIK3CA have
been identiﬁed in NSCLC, no oncogenic mutations have been ver-
iﬁed in p110β, p110δ, or the class IB catalytic isoform p110γ. The
expression of these p110α mutants in cells confers AKT activa-
tion in the absence of growth factor stimulation (Samuels et al.,
2005).
Samuels et al. (2004) sequenced PI3K genes in human can-
cers and corresponding normal tissue and identiﬁed 8 PI3K and
8 PI3K-like genes. Sequences containing the kinase domain of
identiﬁed PI3Ks were extracted from the Celera or Public draft
human genome sequences. Primers for PCR ampliﬁcation and
sequencing were designed using the primer 3 program. They
examined the sequences in a total of 396 tumors. Mutations in
PIK3CA were identiﬁed in 1 (E545K) of 24 lung cancers (4%); and
>75% of alterations occurred in two small clusters in the helical
and kinase domains. Data suggest that mutant PIK3CA was likely
to function as an oncogene in human cancers.
Lee et al. (2005) analyzed somatic mutations of PIK3CA gene
(exons 9, 20) in the 668 tissue samples from gastric, breast,
and hepatocellular carcinomas, acute leukemia, and NSCLC.
The mutational analysis based on PCR, single-strand confor-
mation polymorphism (SSCP) analysis, and sequencing analy-
sis ensures the speciﬁcity of the results. They analyzed 229
NSCLC: 111 squamous cell carcinomas, 108 adenocarcinomas,
and 10 large-cell carcinomas and detected PIK3CA somatic muta-
tions in 3 of 229 NSCLC (1.3%). No signiﬁcant correlation was
found between PIK3CA mutations and the histologic subtypes of
NSCLC. PIK3CA mutation hot spots, E545K, and H1047R, were
detected in 50% of samples.
Gymnopoulos et al. (2007) suggested three groups of PIK3CA
mutants, deﬁned by their location in distinct functional domains
of the protein. They hypothesized that these three groups could
induce a gain in PI3K function by a different molecular mech-
anism. Kawano et al. (2006) genotyped the PIK3CA gene in
Japanese lung cancer patients. The study included 235 lung can-
cer specimens obtained at lung cancer surgery at Nogoya Hospital
from 1997 to 2003. The two PIK3CA mutation hot spots (exon
9, 20) were analyzed by real-time PCR, and then conﬁrmed by
direct sequencing. In exon 9, somatic mutations were found in
eight patients (3 E542K, 3 E545K, 1 E542Q, 1 Q546K); in exon
20 there were no mutations. Around the eight mutations that
objectiﬁed (8/235, 3.4%), two were adenocarcinomas, ﬁve were
squamous cell carcinomas, and one adenosquamous carcinoma.
PIK3CA mutation incidence was signiﬁcantly lower in adenocar-
cinoma (2/135; 1.5%) than in squamous cell carcinoma (5/79;
6.5%, p = 0.0495). Of the eight patients with PIK3CA mutation,
three also harbored EGFR mutations. PIK3CA mutations did not
correlate with gender, age, or smoking status. Overall, there was
no signiﬁcant difference in survival between patients with PIK3CA
wild type (N = 227, 77 died) and patients with PIK3CA mutation
(N = 8, 4 died).
The same group in 2007 investigated PIK3CA copy number
in NSCLC (Kawano et al., 2007). They included 92 Japanese
lung carcinoma patients who had undergone surgery at Nagoya
Hospital. PIK3CA copy number was analyzed by quantitative
real-time PCR; PIK3CA ampliﬁcation (increased PIK3CA copy
number) was deﬁned as >3copies. Incidence of PIK3CA ampli-
ﬁcation was 12% (11/92). Among the 11 patients with PIK3CA
ampliﬁcation, 2 harbored PIK3CA mutations (E542Q, E545K). A
correlation between PIK3CA ampliﬁcation and PIK3CA muta-
tion was not found (p = 0.7534). Among the 11 patients with
PIK3CA ampliﬁcation, no EGFR mutation was found. PIK3CA
ampliﬁcation status was signiﬁcantly different in regard to: gen-
der (male 11/63 versus female 0/29; p = 0.040), smoking history
(current/former 11/59 versus never 0/33; p = 0.021), histology
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SUMMARY
Bibliography PI3KCA mut
NSCLC
PI3KCA mut
SCC
PI3KCA mut
ADC
PI3KCA
amplification
PI3KCA amp
SCC
PI3KCA amp
ADC
Samuels et al. (2004) 1/24 (4%)
Lee et al. (2005) 3/229 (1, 3%)
Kawano et al. (2006) 8/235 (3, 4%) 5/77 (6, 5%) 2/135 (1, 5%)
Kawano et al. (2007) 11/92 (12%) (36%) (1, 6%)
Okudela et al. (2007) 5/139 (3, 6%) 1/35 (2, 9%) 2/85 (2, 5%) 21/115 (18, 3%) (42, 9%) (9, 6%)
Yamamoto et al. (2008) 11/691 (1, 6%) 5/249 (2%) 5/400 (1, 3%) 61/356 (17, 1%) 46/139 (33, 1%) 12/195 (6, 2%)
Angulo et al. (2011) 12/174 (6, 9%) 11/122 (9%) 1/49 (2%) 44/116 (38%)
Carcereny et al. (2011) 6/118 (5, 1%)
Ludovini et al. (2011) 6/145 (4, 1%)
(squamous 10/28 versus adenocarcinoma 1/64; p = 0.0001). Over-
all survival of 92 patients in regard to PIK3CA ampliﬁcation
status showed a signiﬁcant difference in survival between patients
with PIK3CA normal copy number (N = 81, 37 died) versus
patients with PIK3CA ampliﬁcation (N= 11, 9 died), Log-rank
test p = 0.0045. Using cox regression model, only pathologic stage
(p = 0.0337) but not PIK3CA ampliﬁcation (p = 0.2655) was a
prognostic factor.
Okudela et al. (2007) analyzed samples from 148 Japanese
patients with lung cancer who were surgically treated at Hama-
matsu Hospital and Mikatahara Hospital from 1997 to 2006.
Fragments of PI3K were analyzed by PCR; DNA sequence was
analyzed from 139 of the 148 tissues. PIK3CA mutations were
found in 5/139 patients (3.6%). Copy number gains of PIK3CA
locus were found in 21/115 patients by FISH (18.3%). No patients
were found to harbor both PI3KCA mutation and alteration in
copy number.
Yamamoto et al. (2008) analyzed 691 tumor samples
from patients from Japan (N = 323), Taiwan (N = 148), USA
(N = 150), Australia (N = 70) who underwent surgical resection.
They identiﬁed PIK3CA mutations in 11/691 (1.6%). Mutations
occurred in the following histological subtypes: 5 of 249 (2%)
squamous cell carcinoma, 5 of 400 (1.3%) adenocarcinoma, and
1 of 42 (2.4%) other NSCLC. Sufﬁcient DNA was available from
356 of these tumors for PIK3CA gene copy number analysis by
real-time quantitative PCR which was detected in 61/356 (17.1%):
squamous cell carcinoma 46/139 (33.1%) and adenocarcinoma
12/195 (6.2%).
Angulo et al. (2011) analyzed PIK3CA gene mutations (exon
9, 20) in 178 NSCLC: 123 squamous cell carcinoma, 51 adeno-
carcinoma, and 4 large-cell carcinoma. Screening PIK3CA gene
mutation by PCR and direct sequencing was performed in 174.
They identiﬁed 12 PIK3CA mutations (6.9%); in squamous cell
carcinoma 11/122 (9%), and in adenocarcinoma 1/49 (2%). The
analyses of PIK3CA gene ampliﬁcation by FISH was limited
to squamous cell carcinoma and identiﬁed in 44 cases (38%).
Tumors with PI3KCA mutation do not always display ampliﬁca-
tion of the gene; only 2.6% of the samples had both alterations
concomitantly. These results would indicate a complementary
relationship between PIK3CA ampliﬁcation and mutations in
NSCLC.
Carcereny et al. (2011) examined the presence and poten-
tial inﬂuence of PIK3CA mutations on outcome in 118 NSCLC
patients with EGFR mutations treated with erlotinib. They
detected six PIK3CA mutations (5.1%); 84% of patients had
adenocarcinoma. The response rate was 50% for patients with
PIK3CA mutation versus 70% for those with PIK3CA wild type
(p = 0.03). A non-signiﬁcant trend toward shorter progression-
free survival was observed in the six patients with PIK3CA
mutations (9 versus 16months; p = 0.59).
Ludovini et al. (2011) realized a retrospective analysis to
investigate the role of PIK3CA, EGFR, and KRAS gene muta-
tions in predicting response and survival in 166 NSCLC patients
treated with EGFR-TKIs. PIK3CA (exons 9, 20), EGFR, and KRAS
mutations were analyzed using PCR. Of 166 patients, PIK3CA
mutations were evaluated in 145 with 6 found to have PIK3CA
mutations (4.1%). One adenocarcinoma patient with PIK3CA
mutation (M1043I) had EGFR mutation (selection 19). PIK3CA
mutation correlated with shorter median time-to-progression
(2.3months in mutated versus 6months in wild type, HR 2.9,
CI 0.66–12.8; p = 0.01), and worse overall survival (9.9months in
mutated versus 30.2months in wild type, HR 4.76, CI 0.85–26.57;
p< 0.001). The authors suggested that PIK3CA seems to be an
indicator of poor survival in patients with NSCLC treated with
EGFR-TKIs.
In conclusion, several studies have analyzed the PI3K pathway
in NSCLC and reported frequent alterations. At present ongoing
studies are addressing the role of PI3K inhibitors in NSCLC in the
hope that they may lead to targeted therapies in the not too distant
future.
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